151 related articles for article (PubMed ID: 15068993)
1. Itraconazole versus fluconazole for antifungal prophylaxis.
Mossad SB
Ann Intern Med; 2004 Apr; 140(7):580-1; author reply 581-2. PubMed ID: 15068993
[No Abstract] [Full Text] [Related]
2. Itraconazole versus fluconazole for antifungal prophylaxis.
Powers JH; Higgins KM
Ann Intern Med; 2004 Apr; 140(7):580; author reply 581-2. PubMed ID: 15068992
[No Abstract] [Full Text] [Related]
3. Itraconazole versus fluconazole for antifungal prophylaxis.
Karthaus M; Cornely OA; Ullmann AJ
Ann Intern Med; 2004 Apr; 140(7):579-80; author reply 581-2. PubMed ID: 15068991
[No Abstract] [Full Text] [Related]
4. Issues in the design of the fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation.
Marr KA
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S170-5. PubMed ID: 15546113
[TBL] [Abstract][Full Text] [Related]
5. Importance of antifungal prophylaxis in patients who received a nonmyeloablative allogeneic PBSC transplant.
Mossad SB; Avery RK; Bolwell BJ
Clin Infect Dis; 2003 Jun; 36(11):1503-4; author reply 1504. PubMed ID: 12766853
[No Abstract] [Full Text] [Related]
6. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Vardakas KZ; Michalopoulos A; Falagas ME
Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
[TBL] [Abstract][Full Text] [Related]
7. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
[TBL] [Abstract][Full Text] [Related]
8. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
Prentice AG; Glasmacher A; Djulbegovic B
Br J Haematol; 2006 Mar; 132(5):656-8; author reply 658-9. PubMed ID: 16445845
[No Abstract] [Full Text] [Related]
9. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
Morgenstern GR; Prentice AG; Prentice HG; Ropner JE; Schey SA; Warnock DW
Br J Haematol; 1999 Jun; 105(4):901-11. PubMed ID: 10554799
[TBL] [Abstract][Full Text] [Related]
11. Role of new antifungal agents in prophylaxis of mycoses in high risk patients.
van Burik JA
Curr Opin Infect Dis; 2005 Dec; 18(6):479-83. PubMed ID: 16258319
[TBL] [Abstract][Full Text] [Related]
12. Choosing a study population for the evaluation of antifungal prophylaxis.
Cornely OA; Ullmann AJ; Karthaus M
Clin Infect Dis; 2005 Jun; 40(11):1699; author reply 1699-701. PubMed ID: 15889374
[No Abstract] [Full Text] [Related]
13. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Huijgens PC; Simoons-Smit AM; van Loenen AC; Prooy E; van Tinteren H; Ossenkoppele GJ; Jonkhoff AR
J Clin Pathol; 1999 May; 52(5):376-80. PubMed ID: 10560360
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole prophylaxis in hematologic cancer.
van Nieuwkoop C; van Dissel JT
N Engl J Med; 2007 May; 356(21):2215; author reply 2215-8. PubMed ID: 17526089
[No Abstract] [Full Text] [Related]
17. [Cost benefit analysis for prophylactic use of itraconazole versus fluconazole after hematopoietic stem cell transplantation].
Ota S; Wada A; Kosugi M; Matsuoka S; Asanuma S; Fujii S; Noguchi S; Nakata M; Imai K; Hirano T; Kobayashi N; Ogasawara M; Kiyama Y; Kasai M
Rinsho Ketsueki; 2010 Jan; 51(1):63-8. PubMed ID: 20134142
[TBL] [Abstract][Full Text] [Related]
18. Inadequate references in recent article.
de la Cámara R; Jarque I; Grau S; Carreras E
Am J Health Syst Pharm; 2012 Jun; 69(11):917-22; author reply 922. PubMed ID: 22610019
[No Abstract] [Full Text] [Related]
19. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
20. [Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review].
Li Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):627-632. PubMed ID: 28446325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
